HiTT develops projects for top pharma companies, start-ups, government agencies and consultancy firms in the health industry.
Fundations and public institutions
Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.
On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”
This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!